In the BioHarmony Drug Report Database

"Preview" Icon

Belinostat

Beleodaq (belinostat) is a small molecule pharmaceutical. Belinostat was first approved as Beleodaq on 2014-07-03. It is used to treat t-cell lymphoma peripheral in the USA. It is known to target histone deacetylase 8, histone deacetylase 7, histone deacetylase 9, histone deacetylase 4, histone deacetylase 6, histone deacetylase 1, histone deacetylase 3, histone deacetylase 5, and histone deacetylase 2. Beleodaq’s patents are valid until 2027-10-27 (FDA).

 

Trade Name

 

Beleodaq
 

Common Name

 

belinostat
 

ChEMBL ID

 

CHEMBL408513
 

Indication

 

t-cell lymphoma peripheral
 

Drug Class

 

Enzyme inhibitors: inhibitors of histone deacetylase

Image (chem structure or protein)

Belinostat structure rendering